A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
Author:
Affiliation:
1. Chugai Pharmaceutical Co., Ltd. Tokyo Japan
2. F. Hoffmann‐La Roche AG Basel Switzerland
3. Genentech, Inc. South San Francisco California USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1968
Reference52 articles.
1. The Hemophilias — From Royal Genes to Gene Therapy
2. Guidelines for the management of hemophilia
3. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
4. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
5. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group‐Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future;Clinical Pharmacology & Therapeutics;2024-08-15
2. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks;Research and Practice in Thrombosis and Haemostasis;2024-01
3. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial;Blood Journal;2023-12-21
4. Clinical pharmacology of emicizumab for the treatment of hemophilia A;Expert Review of Clinical Pharmacology;2023-08-21
5. DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A;BMJ Open;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3